Subcontract awarded for development of Beta-Thalassaemia treatment

Valesco Pharmaceutical Services has been awarded a subcontract to develop an analytical method, manufacture clinical supplies and test the stability of an investigational drug to treat Beta-Thalassaemia.

Beta-Thalassaemia is a blood disorder that reduces the production of proteins that carry oxygen to cells throughout the body. As a global public health problem it is hoped that through funding it may be possible to advance a potential treatment rapidly to the clinic for this unmet need.

The subcontract award, worth £350,000, is fully funded by the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) via its Therapeutics for Rare and Neglected Diseases (TRND) programme. They have been awarded under a subcontract from Leidos Biomedical Research, prime contractor for the Frederick National Laboratory for Cancer Research.

Velesco Pharmaceutical Services is a privately held contract development and manufacturing organisation with a focus on providing drug product services to pharmaceutical and biotech companies with early stage drug development programmes.